MetaVia (NASDAQ:MTVA) Raised to “Sell” at Wall Street Zen

MetaVia (NASDAQ:MTVA) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a report on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $82.50.

MetaVia Price Performance

Shares of MTVA stock opened at $9.56 on Friday. The firm has a 50-day moving average of $8.94 and a 200-day moving average of $8.72. The company has a market cap of $21.03 million, a P/E ratio of -1.14 and a beta of 0.27. MetaVia has a one year low of $6.05 and a one year high of $30.25.

MetaVia (NASDAQ:MTVA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($2.86) by $1.32. As a group, research analysts expect that MetaVia will post -3.9 earnings per share for the current fiscal year.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new stake in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia at the end of the most recent reporting period. 1.37% of the stock is owned by hedge funds and other institutional investors.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.